Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04374422
Other study ID # AcibademU cov
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 10, 2020
Est. completion date April 12, 2020

Study information

Verified date May 2020
Source Acibadem University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

World Health Organization declared new SARS-CoV-2 infection a pandemic, and many states enacted strict, rules such as border closures, transportation restrictions and quarantine.Many studies in the literature have described the relationship between mass disasters and female sexual behavior, but none have investigated the effect of SARS-CoV-2 pandemic on women's sexual attitude. The aim of this study is therefore to evaluate the effect of SARS-CoV-2 pandemic on female sexual behavior.


Description:

Coronaviruses are a group of RNA viruses that affect mainly the respiratory system and cause the common cold, fever, and coughs in mammals and birds. However, in some cases, coronaviruses are associated with more serious and lethal conditions, such as pneumonia, bronchitis, and severe acute respiratory syndrome. A novel coronavirus (SARS-CoV-2) originating from Wuhan, China led to a global health crisis. At the time of writing, SARS-CoV-2 infected more than two million, resulting in almost 180.000 deaths. World Health Organization declared new SARS-CoV-2 infection a pandemic, and many states enacted strict, rules such as border closures, transportation restrictions, and quarantine.

The term 'sexual behavior' encompasses a large spectrum of actions in which humans present their sexuality. Previous reports have analyzed the effect of mass disasters on female sexual behavior.

Many studies in the literature have described the relationship between mass disasters and female sexual behavior, but none have investigated the effect of the SARS-CoV-2 pandemic on women's sexual attitude. The aim of this study is therefore to evaluate the effect of the SARS-CoV-2 pandemic on female sexual behavior.


Recruitment information / eligibility

Status Completed
Enrollment 58
Est. completion date April 12, 2020
Est. primary completion date April 12, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- married

- above 18 yo

- premenopausal status

Exclusion Criteria:

- urinary incontinence

- history of gynecologic operation

- malignancy

- psychiatric or neurologic disease diagnosis

- being infected by HBV HCV or HIV

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
fsfi survey
sexual behavior Questionaire

Locations

Country Name City State
Turkey Haseki Training and Research Hospital Istanbul

Sponsors (1)

Lead Sponsor Collaborator
Acibadem University

Country where clinical trial is conducted

Turkey, 

References & Publications (2)

Liao X, Wang B, Kang Y. Novel coronavirus infection during the 2019-2020 epidemic: preparing intensive care units-the experience in Sichuan Province, China. Intensive Care Med. 2020 Feb;46(2):357-360. doi: 10.1007/s00134-020-05954-2. Epub 2020 Feb 5. — View Citation

Liu S, Han J, Xiao D, Ma C, Chen B. A report on the reproductive health of women after the massive 2008 Wenchuan earthquake. Int J Gynaecol Obstet. 2010 Feb;108(2):161-4. doi: 10.1016/j.ijgo.2009.08.030. Epub 2009 Nov 4. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary FSFI (Female Sexual Function Index)SCORE difference the FSFI SCORE difference between pre and during pandemic 1 year
See also
  Status Clinical Trial Phase
Terminated NCT04558125 - Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism Phase 4
Recruiting NCT04410510 - P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19 Phase 2/Phase 3
Active, not recruiting NCT04420676 - Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection N/A
Completed NCT04419025 - Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease Phase 2
Completed NCT04395911 - Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections N/A
Completed NCT04425317 - Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients N/A
Withdrawn NCT04456426 - Characteristics of Patients With COVID-19 in Meta State, Colombia
Completed NCT04526769 - Detecting SARS-CoV-2 in Tears
Completed NCT04425720 - Use of Remote Monitoring for COVID-19 Patient N/A
Suspended NCT04385771 - Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation N/A
Completed NCT04419610 - RAS and Coagulopathy in COVID19 Early Phase 1
Completed NCT04546581 - Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC) Phase 3
Completed NCT04435327 - Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
Terminated NCT04530448 - Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization Phase 4
Not yet recruiting NCT04524156 - COVID-19 : Transcutaneous pO2 and pCO2 as Predictive Factors for Acute Respiratory Destress Syndrome in Patients Affected With SARS-Cov-2 N/A
Completed NCT04441710 - Caregiver Serological Monitoring Extended Secondarily to Patients With the SARS-CoV-2 Coronavirus
Completed NCT04357834 - WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
Not yet recruiting NCT04392427 - New Antiviral Drugs for Treatment of COVID-19 Phase 3
Terminated NCT04614025 - Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19 Phase 2
Completed NCT04402957 - LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19) Phase 2